DPI-3290

Source: Wikipedia, the free encyclopedia.
DPI-3290
Identifiers
  • 3-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide
JSmol)
  • C[C@H]1CN([C@@H](CN1[C@@H](C2=CC(=CC=C2)O)C3=CC=CC(=C3)C(=O)N(C)C4=CC(=CC=C4)F)C)CC=C
  • InChI=1S/C30H34FN3O2/c1-5-15-33-19-22(3)34(20-21(33)2)29(24-10-7-14-28(35)17-24)23-9-6-11-25(16-23)30(36)32(4)27-13-8-12-26(31)18-27/h5-14,16-18,21-22,29,35H,1,15,19-20H2,2-4H3/t21-,22+,29-/m1/s1 ☒N
  • Key:LZXRQLIIMYJZDA-UETOGOEVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

DPI-3290 was discovered by scientists at Burroughs Wellcome and licensed to Delta Pharmaceutical

respiratory depression.[3]

DPI-3290 acts as an

δ-opioid receptor, with an IC50 of 6.2nM at μ and 1.0nM at δ.[4]

See also

References

  1. ^ US Patent 5552404 - Opioid compounds and methods for using same
  2. S2CID 93569860
    .
  3. S2CID 45159720
    .
  4. PMID 16584118
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=DPI-3290&oldid=1084238483"